Caribou Biosciences Reports Third Quarter 2026 Financial Results
Caribou Biosciences reported its financial results for the third quarter of 2026, highlighting a net loss of $26.6 million and ongoing strategic restructuring efforts.
Stocks · News reference
This Voya Financial Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
Analysts downgraded Voya, Pacira, Genworth, and more, with price-target changes for several.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Pacira BioSciences Reports Third-Quarter 2026 Financial Results
Pacira BioSciences announced its financial results for the third quarter of 2026, reporting $176.65 million in revenue and $0.70 in diluted earnings per share.
Corporate Insight Releases Research Series on AI Leaders in Financial Services
Corporate Insight released research evaluating AI-powered tools across financial services, identifying leaders in virtual assistants, fintech platforms, and AI search retrieval. Fidelity and Voya Financial lead in retirement plan assistants, Lively excels in HSA virtual assistants, Charles Schwab and Robinhood lead in fintech customer service, and Fidelity, TruStage, and USAA top annuity AI content retrieval. The research highlights that leading tools complete tasks in-chat while median performers lag significantly behind.
Barclays Adjusts Price Target for South Bow
Barclays maintained its 'Underweight' rating on South Bow while raising its price target to $34 from $33.
8-K filing — Pacira BioSciences, Inc. (PCRX)
Filed: 2026-11-05 AccNo: 0001628280-26-071129 Size: 152 KB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Barclays Maintains Underweight on South Bow, Raises Price Target to $34